Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2003
12/03/2003EP1367056A1 Drugs that enhance synaptic responses mediated by AMPA receptors
12/03/2003EP1367055A1 Isoquinolinyl carboxamides and their use as anticonvulsants
12/03/2003EP1367054A1 Heterocyclic factor Xa inhibitors
12/03/2003EP1367051A2 Inhibitors of tumor necrosis factor alpha
12/03/2003EP1367046A1 Disubstituted lavendustin A analogs and pharmaceutical compositions comprising the analogs
12/03/2003EP1366768A1 Compositions for therapeutic use comprising a vitamin, a metal salt and insulin or a growth hormone
12/03/2003EP1366767A1 Aqueous suspension eyedrops and process for producing the same
12/03/2003EP1366766A1 Inhibitors of IMPDH enzyme
12/03/2003EP1366765A1 Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing
12/03/2003EP1366762A1 Adhesive patch
12/03/2003EP1366760A1 Tablets quickly disintegrated in oral cavity
12/03/2003EP1366743A1 Use of a derivative of 7-oxydated DHEA for treating dry skin
12/03/2003EP1366366A2 Compositions and methods for the diagnosis, treatment and prevention of steroid hormone responsive cancers
12/03/2003EP1366180A2 Use of mutations of mec-1 and its related genes in the identification of compounds for treatment of disease
12/03/2003EP1366162A2 Putative proteins and nucleic acids encoding same
12/03/2003EP1366158A2 Trp8, trp9 and trp10, markers for cancer
12/03/2003EP1366082A1 Highly sulfated derivatives of k5 polysaccharide and their preparation
12/03/2003EP1366081A2 Grain fractionation methods and products
12/03/2003EP1366079A2 Nuclear hormone receptor ligand binding domain
12/03/2003EP1366061A2 Method of treating amyloid $g(b) precursor disorder
12/03/2003EP1366055A2 Antiviral agents for treatment of flaviviridae infections
12/03/2003EP1366052A2 Novel multi-ring organic compounds for regulating gut motility and food intake
12/03/2003EP1366051A2 Solid forms of tin ethyl etiopurpurin and processes for producing such forms
12/03/2003EP1366050A2 Condensed pyrazindione derivatives as pde inhibitors
12/03/2003EP1366049A2 Pirazino[1'2':1,6]pyrido[3,4-b]indole derivatives
12/03/2003EP1366048A2 Pyrazolopyridine derivatives
12/03/2003EP1366047A1 Thiazole compounds as tgf-beta inhibitors
12/03/2003EP1366045A2 Efficient process for the preparation of a factor xa inhibitor
12/03/2003EP1366044A1 8-[4-[3-(5-fluoro-1h-indol-3-yl)propyl]-1-piperazinyl]-2-methyl-2h-1, 4-benzoxazin-3(4h)-one methanesulfonate with high affinity for the dopamine d2 receptor and the serotonin reuptake site
12/03/2003EP1366040A2 Amorphous form of cell cycle inhibitor
12/03/2003EP1366039A1 Piperazinylcarbonylquinolines and -isoquinolines
12/03/2003EP1366036A2 Compounds having activity as inhibitors of cytochrome p450rai
12/03/2003EP1366035A1 Preparation of warfarin sodium from warfarin sodium-2-propanol clathrate by solvent expulsion
12/03/2003EP1366030A2 Melanin concentrating hormone receptor ligands
12/03/2003EP1366029A1 Substituted 2-oxo-3-phenyl-5-carbonylaminomethyl-1,3-oxazolins and the utilization thereof as anticoagulant and antithrombotic agents
12/03/2003EP1366028A1 Diaminoquinazoline esters for use as dihydrofolate reductase inhibitors
12/03/2003EP1366027A1 Combi-molecules having signal transduction inhibitory properties and dna damaging properties
12/03/2003EP1366025A1 Agonists of beta-adrenoceptors
12/03/2003EP1366024A2 Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
12/03/2003EP1366021A2 Substituted diarylureas as stimulators for fas-mediated apoptosis
12/03/2003EP1366020A1 Urea derivatives having vanilloid receptor (vr1) antagonist activity
12/03/2003EP1366018A1 Omega-aminoalkylamides of r-2-aryl-propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells
12/03/2003EP1366016A2 Process for the preparation of arylethanoldiamines useful as agonists of the beta-3-adrenoceptor
12/03/2003EP1366012A2 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders
12/03/2003EP1366007A2 Compounds with high monoamine transporter affinity
12/03/2003EP1365841A1 Essential n-3 fatty acids in cardiac insufficiency and heart failure therapy
12/03/2003EP1365812A2 Pharmaceutical composition having reduced tendency for drug crystallization
12/03/2003EP1365811A2 Compositions containing alpha-2-adrenergic agonist components
12/03/2003EP1365810A1 Calcium supplementation to reduce prostate cancer risk
12/03/2003EP1365809A2 Methods for reducing chronic stress in mammals
12/03/2003EP1365808A2 Compositions for antitumour treatment containing ecteinascidin 743
12/03/2003EP1365806A2 Use of no acttivators for treatment and prevention of gastrointestinal disorders
12/03/2003EP1365798A2 Use of serp-1 in combination with an immunosuppressant for influencing inflammatory and immune reactions
12/03/2003EP1365796A2 Inhibition of mitogen-activated protein kinase (mapk) pathway: a selective therapeutic strategy against melanoma
12/03/2003EP1365787A2 New uses for amino acid anticonvulsants for treatment of pain
12/03/2003EP1365784A1 Methods and devices for tissue repair
12/03/2003EP1365781A1 Acrochordon alleviation
12/03/2003EP1365779A1 Pharmaceutical or dietary composition containing a vegetable oil, in particular olive oil, and sitosterol
12/03/2003EP1365778A2 Treating pulmonary disorders with gaseous agent causing repletion of gsno
12/03/2003EP1365777A2 Proteoglycan compositions for treatment of inflammatory conditions
12/03/2003EP1365776A2 Use of an adenosine a3 receptor agonist for inhibition of viral replication
12/03/2003EP1365775A1 Telithromycin suspension with a masked taste
12/03/2003EP1365774A2 Use of zwitterionic polysaccharides for the specific modulation of immune processes
12/03/2003EP1365772A2 Stabilized brivudine topical formulations containing metal oxide pigments
12/03/2003EP1365771A1 Method of treating certain eye diseases
12/03/2003EP1365769A1 A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis
12/03/2003EP1365768A2 Use of erss-selective ligands for regulating fertility and compounds useful therefore
12/03/2003EP1365767A2 Pharmaceutical formulation comprising r-salmeterol and fluticasone propionate
12/03/2003EP1365766A2 Pharmaceutical composition for treatment of phimosis using topical corticosteroid
12/03/2003EP1365765A2 The use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment
12/03/2003EP1365764A1 Oral pharmaceutical composition of cefpodoxime proxetil
12/03/2003EP1365763A1 Farnesyl protein transferase inhibitor combinations with antiestrogen agents
12/03/2003EP1365762A1 Method for increasing leptin levels using nicotinic acid compounds
12/03/2003EP1365761A1 Therapeutic combination of amlodipine and benazepril
12/03/2003EP1365760A1 Preparations and use of an ah receptor ligand, 2-(1'h-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester
12/03/2003EP1365759A2 Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
12/03/2003EP1365758A2 Method for modulation, stimulation, and inhibition of glutamate reuptake
12/03/2003EP1365757A1 New use
12/03/2003EP1365756A2 Method of treating the syndrome of type 2 diabetes in humans
12/03/2003EP1365755A2 Use of pyrimidine nucleosides and/or the prodrugs thereof for combating the side-effects of haart (highly active anti-retroviral therapy) and other anti-viral therapies
12/03/2003EP1365754A2 Inhibition of proteasomes to prevent restenosis
12/03/2003EP1365753A2 Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer
12/03/2003EP1365752A2 Methods for the treatment of a traumatic central nervous system injury with e.g. allopregnanolone
12/03/2003EP1365751A2 Granules and granules coated with a masked taste
12/03/2003EP1365749A2 Process for preparing pharmaceutical compositions for use with soft gelatin formulations
12/03/2003EP1365748A2 Particulate composition of eletriptan showing a sigmoidal pattern of controlled release
12/03/2003EP1365746A1 Pharmaceutical composition which comprise a solid dispersion of a hydroxypropylmethylcellulose phthalate polymer
12/03/2003EP1365745A2 Stabilized pharmaceutical and thyroid hormone compositions and method of preparation
12/03/2003EP1365740A1 Rapid-onset medicament for the treatment of sexual dysfunction
12/03/2003EP1365739A1 Composition for rectal delivery of an oxazolidinone antibacterial drug
12/03/2003EP1365737A2 Stable salts of o-acetylsalicyclic with basic amino acids
12/03/2003EP1365726A2 Method for evaluating therapeutic efficacy
12/03/2003EP1365705A1 Injectable pharmaceutical composition comprising microparticles or microdroplets of camptothecin
12/03/2003EP1365704A2 Radiation cross-linked hydrogels
12/03/2003EP1365651A1 Composition and methods for modulation of vascular structure and/or function
12/03/2003EP1283838B1 Piperazine and piperidine compounds
12/03/2003EP1257555B1 Pyrimidine compounds and their use as modulators of chemokine receptor activity
12/03/2003EP1250125B1 Pharmaceutical compositions comprising terbinafine
12/03/2003EP1224181B1 Substituted pyrroles as antiproliferative agents for the treatment of cancer
12/03/2003EP1212336B1 Method for the production and use of spherical telithromycin clusters in the preparation of pharmaceutical forms
1 ... 5256 5257 5258 5259 5260 5261 5262 5263 5264 5265 5266 5267 5268 5269 5270 5271 5272 5273 5274 5275 5276 ... 7860